Bill Roark, chair of the firm’s cannabis practice and co-chair of the Pennsylvania Bar Association’s Medical Marijuana and Hemp Law Committee, is quoted in the April 6, 2020 Philadelphia Inquirer article entitled “DEA relaxes rules for the only federally approved drug derived from marijuana.” Bill was quoted as stating, “This ruling doesn’t have a seismic impact. It really only impacts GW Pharma. It makes their product more accessible for patients. It means doctors don’t have to go to through the drug-monitoring program to make certain their patients don’t have a drug history. And a parent will now be able to go from pharmacy to pharmacy rather than having one specific source.”

To read the entire article, please click here.